Becotatug vedotin shows 20.9% objective response in recurrent head and neck squamous cell carcinoma after prior therapy
For patients with advanced head and neck cancer, a new drug showed a 21% response rate in early testing
This multicenter, Phase IIa trial evaluated intravenous becotatug vedotin in 67 patients with recurrent or metastatic squamous cell carcinom…
A new drug shrank tumors in 21% of patients with advanced head and neck cancer who had run out of standard treatment options.
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Advanced experimental models and computational tools provide dynamic frameworks for understanding oral disease progression
New Research Tools Help Map Complex Oral Diseases
This mini-review examines the integration of advanced experimental models, such as organ-on-chip systems and patient-derived organoids, with…
Advanced modeling and AI tools are helping researchers better understand the molecular causes behind conditions like gum disease and oral ca…
Microbial metabolites may promote or suppress cancer progression through inflammation, DNA damage, or immune modulation
Microbial metabolites may drive cancer growth or stop it through inflammation and DNA damage
This narrative review examines the role of microbial metabolites in carcinogenesis and cancer progression across multiple malignancies. The …
Microbial metabolites can promote cancer growth via inflammation or suppress it through immune changes, but we need more proof before using …
Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis
Local brain treatments linked to modest survival gains in rare head and neck cancer cases
This retrospective cohort analysis evaluated 201 patients with head and neck squamous cell carcinoma and brain metastasis from three tertiar…
Local brain treatments linked to lower death risk for rare head and neck cancer patients who develop brain metastases, though most still die…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Molecular markers may improve risk assessment in oral potentially malignant disorders
Molecular tools may improve risk assessment for oral lesions
This narrative review examines the limitations of conventional histopathological grading for oral potentially malignant disorders (OPMDs) an…
A review suggests molecular methods could better assess risk for oral potentially malignant disorders where standard grading is unreliable.
Aspiration pneumonia affects 74.8% of head and neck cancer patients after chemoradiotherapy
Aspiration pneumonia strikes most head and neck cancer patients after chemoradiation
This supplementary analysis of a phase II/III trial in Japan found that 74.8% of 151 patients with resected high-risk head and neck cancer d…
Three in four head and neck cancer patients develop aspiration pneumonia after chemoradiation. Severe swallowing problems and reconstruction…
Radiotherapy and chemotherapy show no clear link to obstructive sleep apnea in head and neck cancer patients
Radiation for head and neck cancer may raise sleep apnea risk
This scoping review with exploratory meta-analysis of 13 studies found no significant association between radiotherapy or chemotherapy and i…
A review of 13 studies suggests a possible link between radiation for head and neck cancer and mild sleep apnea, but the evidence is too wea…
20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
Shorter radiation schedule works as well for head and neck cancer
This randomized, open-label, Phase 3 noninferiority trial enrolled 792 patients with locally advanced head and neck squamous cell carcinoma …
A shorter radiation plan for head and neck cancer showed the same effectiveness as a longer schedule while reducing late side effects.
Robot-assisted oesophagectomy shows non-inferior survival in oesophageal squamous cell carcinoma
Robot-assisted surgery may improve survival for oesophageal cancer patients
A randomised trial compared robot-assisted versus thoracoscopic oesophagectomy for resectable oesophageal squamous cell carcinoma. The autho…
A large trial found robot-assisted oesophagectomy linked to higher five-year survival than thoracoscopic surgery for oesophageal squamous ce…
Scoping review of AI for head and neck cancer risk stratification
AI techniques show promise for staging head and neck cancer
This scoping review synthesized 44 studies on AI techniques for risk stratification in head and neck cancer. The authors found moderate to h…
A review of 44 studies suggests artificial intelligence could help predict cancer spread in head and neck cases, though more testing is need…
Narrative review covers diagnostic and treatment strategies for metastatic head and neck cancer with no identifiable primary tumor
Doctors use many tools to treat head and neck cancer when the main tumor is hidden
This narrative review addresses diagnostic and treatment strategies for metastatic cases of head and neck cancer with no identifiable primar…
When head and neck cancer spreads but the original spot is missing, doctors use many tools. Imaging, special tests, and surgery help find th…
Evidence mapping review on nutritional prehabilitation for head and neck cancer patients
Nutritional prehabilitation improves outcomes for head and neck cancer patients
This evidence mapping review synthesized 6 systematic evaluations, 13 randomized controlled trials, and 4 observational studies on pretreatm…
Nutritional prehabilitation helps patients with head and neck cancer by improving their nutritional status and quality of life while reducin…
Questions about Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Full answer →